Therapeutic effects of antigen affinity-purified polyclonal anti-receptor of advanced glycation end-product (RAGE) antibodies on cholestasis-induced liver injury in rats.
RatOtherWistarMaleSubcutaneous injection0.5 mg/kgCommenced after bile duct ligation
Model: Bile duct ligation-induced cholestatic liver injury
Anti-RAGE improved survival and gross liver appearance, attenuated necrosis, inflammation, fibrosis and duct proliferation, reduced hepatic interleukin-1 beta, Col1a1, cholesterol 7 alpha-hydroxylase and the TIMP-1 to MMP ratio, and inhibited hepatic stellate cell proliferation in vivo and in vitro.
Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.